遗传 ›› 2007, Vol. 29 ›› Issue (11): 1357-1361.doi: 10.1360/yc-007-1357

• 研究报告 • 上一篇    下一篇

类风湿性关节炎患者外周血单个核细胞 IL-10基因启动子甲基化状态研究

付丽红; 丛斌; 甄艳凤; 李淑瑾; 马春玲; 倪志宇; 张国忠; 左敏; 姚玉霞   

  1. 河北医科大学法医学系,石家庄 050017

  • 收稿日期:2007-03-28 修回日期:2007-08-10 出版日期:2007-11-10 发布日期:2007-11-10
  • 通讯作者: 丛斌

Methylation status of the IL-10 gene promoter in the peripheral blood mononuclear cells of rheumatoid arthritis patients

FU Li-Hong; CONG Bin; ZHEN Yan-Feng; LI Shu-Jin; MA Chun-Ling; NI Zhi-Yu;
ZHANG Guo-Zhong; ZUO Min; YAO Yu-Xia
  

  1. Department of Forensic Medicine, Hebei Medical University, Shijiazhuang 050017, China
  • Received:2007-03-28 Revised:2007-08-10 Online:2007-11-10 Published:2007-11-10
  • Contact: CONG Bin

摘要:

白细胞介素-10(interleukin-10,IL-10)是在类风湿性关节炎中发挥重要免疫调节作用的细胞因子,其基因失活与已分化的Th1和Th2细胞染色质结构重塑有关。为了探讨IL-10基因启动子甲基化及基因失活在类风湿性关节炎(Rheumatoid Arthritis,RA)发病和进展中的作用,采用逆转录聚合酶链反应(RT-PCR)、酶联免疫吸附实验(enzyme linked immunosorbent assay,ELISA)及甲基化特异性聚合酶链反应(MSP), 分别检测34例类风湿性关节炎患者和30例健康人外周血单个核细胞 IL-10 mRNA、蛋白表达水平及基因启动子甲基化状态。结果显示,病例组IL-10 mRNA及蛋白表达均低于健康对照组,无统计学差异(P>0.05)。病例组甲基化率(85.29%)高于健康对照组(43.33%), 具有统计学差异(x2 =12.439,P=0.000)。IL-10基因启动子甲基化状态与其mRNA表达呈显著负相关(r=-0.579, P=0.001), 与所累关节数显著相关,但与血沉(ESR)、C反应蛋白(CRP)、类风湿因子(RF)、年龄均无相关性(P>0.05)。IL-10 mRNA表达与年龄、所累关节数、ESR、CRP及RF均无相关性(P>0.05)。上述结果提示,启动子甲基化可能是IL-10基因失活的重要机制,IL-10基因异常高甲基化状态可能参与了RA的发生发展。

关键词: 类风湿性关节炎, 白细胞介素-10, 甲基化特异性聚合酶链反应

Abstract:

Interleukin 10(IL-10), as an immunoregulatory cytokine, plays an important role in rheumatoid arthritis (RA). IL-10 gene silencing is associated with the chromatin remodeling in differentiated Th1 and Th2 cells. To explore the relationship between IL-10 promoter methylation and gene silencing in the pathogenesis of RA, IL-10 mRNA, protein expression and promoter methylation status were analyzed in the peripheral blood mononuclear cells (PBMC) of 34 RA patients and 30 healthy controls by reverse transcriptase-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA) and methylation specific polymerase chain reaction (MSP), respectively. The results showed that IL-10 mRNA and protein expression in RA patients seemed to be lower than that in healthy controls, but there was no statistically significant difference (P>0.05). IL-10 promoter was methylated at a frequency of 85.29% in RA cases, which was significantly higher than the percentage in healthy controls (43.33%) (x2 =12.439, P=0.000). IL-10 promoter methylation and mRNA expres-sion showed a strong negative correlation (r=-0.579, P=0.001). IL-10 promoter methylation, but not mRNA expression, also correlated statistically with the number of arthritic joints. However, there were no statistical correlations between IL-10 promoter methylation (or mRNA expression) and clinical indices of RA, such as the levels of erythrocyte sedimentation rate (ESR), C reactive protein (CRP) and rheumatic factor (RF) or age (P>0.05). These findings suggest that promoter methyla-tion may be a crucial mechanism of IL-10 gene inactivation in RA and IL-10 promoter CpG island hypermethylation might be involved in the occurrence and development of RA.